DM
KALV

Deerfield Management’s KalVista Pharmaceuticals KALV Stock Holding History

Deerfield Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,255
Closed -$153K – 262
2024
Q3 		$153K Buy
13,255
+2,414
+22% +$30.4K ﹤0.01% 430
2024
Q2 		$128K Sell
10,841
-4,512
-29% -$52.7K ﹤0.01% 421
2024
Q1 		$182K Buy
+15,353
New +$205K ﹤0.01% 340
2022
Q2 		– Sell
-830,472
Closed -$12.2M – 131
2022
Q1 		$12.2M Sell
830,472
-344,659
-29% -$4.95M 0.27% 65
2021
Q4 		$15.5M Sell
1,175,131
-988,423
-46% -$15.7M 0.33% 69
2021
Q3 		$37.8M Hold
2,163,554
– – 0.74% 40
2021
Q2 		$51.8M Buy
2,163,554
+1,143,549
+112% +$29.9M 0.92% 33
2021
Q1 		$26.2M Buy
+1,020,005
New +$26.8M 0.55% 62
2019
Q4 		– Sell
-890,668
Closed -$10.3M – 89
2019
Q3 		$10.3M Sell
890,668
-327,000
-27% -$5.28M 0.42% 59
2019
Q2 		$27M Buy
1,217,668
+567,668
+87% +$13.3M 0.97% 35
2019
Q1 		$18.6M Hold
650,000
– – 0.71% 44
2018
Q4 		$12.8M Hold
650,000
– – 0.51% 54
2018
Q3 		$14.4M Buy
+650,000
New +$8.79M 0.51% 60

Other funds holding KALV

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Deerfield Management's KALV Position: Q4 2024 in Review

Deerfield Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2024, closing a stake of 13,255 shares — an estimated $153K sold.

Deerfield Management first reported a position in KALV in Q3 2018 and held it in 13 quarters. The position peaked at $51.8M in Q2 2021. 130 funds tracked by Wall St. Rank hold KALV as of Q4 2024.

  • Deerfield Management reported no remaining KalVista Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Deerfield Management sold 13,255 KalVista Pharmaceuticals shares in Q4 2024, an estimated $153K.
  • Deerfield Management first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 13 quarters.
  • Deerfield Management's KalVista Pharmaceuticals position peaked at $51.8M in Q2 2021.
  • 130 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.